We serve Chemical Name:methyl 3-nitronaphthalene-1-carboxylate CAS:13772-63-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:methyl 3-nitronaphthalene-1-carboxylate
CAS.NO:13772-63-9
Synonyms:3-Nitro-naphthoesaeure-1-methylester;3-Nitro-1-naphthoesaeure-methylester;methyl 3-nitro-1-naphthoate;methyl 3-nitro-5,6,7,8-tetrahydro-1-naphthoate;3-nitro-1-naphthoate
Molecular Formula:C12H9NO4
Molecular Weight:231.20400
HS Code:2916399090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:391.9ºC at 760 mmHg
Density:1.334g/cm3
Index of Refraction:1.639
PSA:72.12000
Exact Mass:231.05300
LogP:3.05780
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 3-Nitro-naphthoesaeure-1-methylester chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-nitro-1-naphthoate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,methyl 3-nitro-5,6,7,8-tetrahydro-1-naphthoate Use and application,3-nitro-1-naphthoate technical grade,usp/ep/jp grade.
Related News: And finally, CHMP also concluded its investigation into bluebird bio’s Zynteglo, finding no evidence that it causes a blood cancer known as acute myeloid leukemia. 2-ammonium-1-hydroxyethane-1,1-diyl-biphosphonic acid manufacturers Findings show that there is a decline in the body’s immunity over time. The aim of the supplementary dose is to build it up again, and thus reduce the chances of infection and serious illness significantly,” Bennett told a news conference.
“I call on all the seniors who received the second dose, go get the supplementary one,” he said. “My first telephone call, after I finish speaking, will be to the person dearest to me, my mother, so that I can take her to be vaccinated immediately. 1,1′-Sulfanediylbis(2,3,5,6-tetrafluorobenzene) suppliers TULIP-2 assessed the effect of anifrolumab in reducing disease activity as measured by the BILAG-Based Composite Lupus Assessment (BICLA) scale. In TULIP-1, 457 eligible patients were randomised (1:2:2) and received a fixed-dose intravenous infusion of 150mg anifrolumab, 300mg anifrolumab or placebo every four weeks, 4R,5S-1-N-(tert-butoxycarbonyl)-2,2-dimethyl-4-phenyl-5-oxazolidinecarboxylic acid vendor & factory.
“I call on all the seniors who received the second dose, go get the supplementary one,” he said. “My first telephone call, after I finish speaking, will be to the person dearest to me, my mother, so that I can take her to be vaccinated immediately. 1,1′-Sulfanediylbis(2,3,5,6-tetrafluorobenzene) suppliers TULIP-2 assessed the effect of anifrolumab in reducing disease activity as measured by the BILAG-Based Composite Lupus Assessment (BICLA) scale. In TULIP-1, 457 eligible patients were randomised (1:2:2) and received a fixed-dose intravenous infusion of 150mg anifrolumab, 300mg anifrolumab or placebo every four weeks, 4R,5S-1-N-(tert-butoxycarbonyl)-2,2-dimethyl-4-phenyl-5-oxazolidinecarboxylic acid vendor & factory.
